Ernst Wastler - Fresenius CEO

All Insiders . USA . 
Stock . Fresenius SE Co . Stakeholders . Insider . Ernst Wastler
FSNUF Stock  USD 34.66  0.00  0.00%   

CEO

Dr. Ernst Wastler is Member of the Management Board and Chief Executive Officer of Business segment Fresenius Vamed at Fresenius SE Co KGaA since January 1, 2008 since 2008.
Age 65
Tenure 16 years
Professional MarksPh.D
Phone49 6172 608 2487
Webhttps://www.fresenius.com
Wastler became Member of the VAMED AG Management Board in 1998 and was responsible for projects and services central Europe. Prior to that, he held several management positions at international business segments of the VAMED Group. His career began in 1981 in international consulting, engineering and project management at Austroplan GmbH in Vienna. Currently, he serves as Deputy Chairman of the Supervisory Board of Charite CFM Facility Management GmbH, as well as Chairman of the Supervisory Board of VAMEDKMB Krankenhausmanagement und Betriebsfuehrungges. m.b.H. He studied International Business at Wirtschaftsuniversitaet Wien and earned a Doctorate there in 1983.

Fresenius Management Efficiency

The company has return on total asset (ROA) of 0.0292 % which means that it generated a profit of $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0793 %, meaning that it generated $0.0793 on every $100 dollars invested by stockholders. Fresenius' management efficiency ratios could be used to measure how well Fresenius manages its routine affairs as well as how well it operates its assets and liabilities.
Fresenius SE Co has accumulated 27.16 B in total debt with debt to equity ratio (D/E) of 0.89, which is about average as compared to similar companies. Fresenius SE has a current ratio of 1.29, suggesting that it is not liquid enough and may have problems paying out its financial obligations in time and when they become due. Debt can assist Fresenius until it has trouble settling it off, either with new capital or with free cash flow. So, Fresenius' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Fresenius SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Fresenius to invest in growth at high rates of return. When we think about Fresenius' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

CEO Age

Javier RodriguezDaVita HealthCare Partners
53
Francesco MeoFresenius SE Co
60
Brent CFARegional Health Properties
48
Susan SalkaAMN Healthcare Services
56
Caroline GraceAMN Healthcare Services
55
Dirk CPAAddus HomeCare
68
Christopher ReadingUS Physicalrapy
60
Paul KusserowAmedisys
63
Christopher ChristensenThe Ensign Group
55
Heath CPAModivCare
53
Steven Sellagilon health
58
Richard AshworthAmedisys
49
Dirk AllisonAddus HomeCare
68
KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Hhe, Germany. Fresenius operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange. It employs 318647 people. Fresenius SE Co [FSNUF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity0.0793
Return On Asset0.0292

Fresenius SE Leadership Team

Elected by the shareholders, the Fresenius' board of directors comprises two types of representatives: Fresenius inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius' management team and ensure that shareholders' interests are well served. Fresenius' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius' outside directors are responsible for providing unbiased perspectives on the board's policies.
Francesco Meo, Member of the Management Board - Fresenius Management SE and CEO of Fresenius Helios
Michael Sen, Pres CEO
Sara Hennicken, Chief Officer
Helen Giza, Member SE
Ernst Wastler, Member of the Management Board - Fresenius Management SE and CEO of Fresenius Vamed
Sebastian Biedenkopf, HR, Officer
Matthias Link, Sr Communications
Markus Georgi, Senior Vice President Investor Relations
Carla Kriwet, Members SE

Fresenius Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Fresenius a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0793
Return On Asset0.0292
Profit Margin0.04 %
Operating Margin0.09 %
Current Valuation43.74 B
Shares Outstanding563.24 M
Shares Owned By Insiders26.90 %
Shares Owned By Institutions36.39 %
Price To Earning7.29 X
Price To Book0.71 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Fresenius Pink Sheet

Fresenius financial ratios help investors to determine whether Fresenius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fresenius with respect to the benefits of owning Fresenius security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY